Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5% – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shot up 5% during mid-day trading on Tuesday . The company traded as high as $26.80 and last traded at $26.71. 62,092 shares traded hands during trading, a decline of 68% from the average session volume of 196,014 shares. The stock had previously closed at $25.43.

Analyst Upgrades and Downgrades

Several brokerages have commented on DNTH. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price on the stock. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Oppenheimer assumed coverage on Dianthus Therapeutics in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 price target on the stock. Finally, Wedbush reduced their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Nine research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $45.13.

Dianthus Therapeutics Trading Up 0.2 %

The stock’s 50 day moving average price is $27.77 and its 200 day moving average price is $26.10. The company has a market capitalization of $822.65 million, a price-to-earnings ratio of -4.81 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -2.28 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Dianthus Therapeutics by 860.5% during the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after purchasing an additional 72,509 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its position in Dianthus Therapeutics by 281.9% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock worth $1,022,000 after buying an additional 29,159 shares during the last quarter. American Century Companies Inc. raised its stake in Dianthus Therapeutics by 38.6% in the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after buying an additional 8,473 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Dianthus Therapeutics in the second quarter valued at approximately $112,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.